Idorsia’s Insomnia Drug Daridorexant Among 14 Hopefuls For EU Verdict
Immunocore’s Tebentafusp Could Also Get A Marketing Recommendation
Executive Summary
The European Medicines Agency will likely decide this week whether to recommend for pan-EU approval new treatments for insomnia, uveal melanoma, migraine and advanced prostate cancer.
You may also be interested in...
EMA Thumbs Up For Idorsia’s Insomnia Drug And Immunocore’s Uveal Melanoma Treatment
An insomnia drug to improve daytime functioning, a treatment for a rare type of eye cancer, and an oral migraine drug for both acute and preventive treatment are among 13 new products recommended for pan-EU approval.
Arimoclomol & Ipique Developers To Make Their Case For EU Approval
The sponsors of two investigational drugs that have previously experienced key regulatory setbacks are set to give oral explanations to the European Medicines Agency about why they believe their products should be approved in the EU.
Arimoclomol & Ipique Developers To Make Their Case For EU Approval
The sponsors of two investigational drugs that have previously experienced key regulatory setbacks are set to give oral explanations to the European Medicines Agency about why they believe their products should be approved in the EU.